Modeling the specific CD4+ T cell response against a tumor neoantigen

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• CD4(+) T cell antitumor activity is recognized, but mechanisms are often studied in artificial mouse models.
• Transplanted tumor models cause early antigen release and inflammation, unlike slow-growing human tumors.
• This artificial priming hinders studying immune system-tumor interactions in a steady state.

Purpose of the Study:

• To develop a more accurate model for studying immune responses to tumors.
• To investigate immune cell activation by neoantigens presented in established tumors.
• To assess the potential for therapeutic vaccination against tumor neoantigens.

Main Methods:

• Generated a mouse cell line with inducible expression of a model antigen (DBY).
• Induced antigen expression days after tumor implantation to mimic steady-state tumor growth.
• Tracked antigen presentation, lymph node activation, and T cell responses in vivo.

Main Results:

• Inducible antigen expression allowed for prolonged antigen presentation (over 4 weeks).
• Induced neoantigen reached lymph nodes, activating naive CD4(+) T cells to proliferate and recirculate.
• Observed Th1/Th17 effector cells in tumor-draining lymph nodes and tumors, with no de novo regulatory T cell induction.

Conclusions:

• Naive CD4(+) T cells are not tolerized when neoantigens arise in established tumors.
• The immune system actively responds to neoantigens in a more realistic tumor model.
• This research supports the development of therapeutic vaccines targeting tumor-specific neoantigens.